We next evaluated the antigenic reactivity of the synthetic S1P4 and S2P6 peptides using a group of infection-naïve individuals who had been immunized with comirnaty vaccine in January–February 2021 (n = 9, median age: 50, female to male ratio: 0.9) (Table S4). The gene discussed is S1PR4; the disease is infection.